Concepedia

Shengqing Gu

SG

Statistics

Publications

39

Citations

8.1K

H-Index

25

Active since

2011

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Dana-Farber/Harvard Cancer Center

Tongji University

Massachusetts General Hospital

Shengqing Gu is an author at Dana-Farber Cancer Institute specializing in life sciences, oncology, and cancer immunology.

ORCID

Publications per year

2011–2024

39

Publications

39

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang, Shengqing Gu, Deng Pan et al. · Nature Medicine · 2018 · 5.6K citations · Full text

, , +14

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Shengqing Gu, Wubing Zhang, Xiaoqing Wang et al. · Cancer Discovery · 2021 · 282 citations · Full text

, , +16

Landscape of B cell immunity and related immune evasion in human cancers

Xihao Hu, Jian Zhang, Jin Wang et al. · Nature Genetics · 2019 · 221 citations · Full text

, , +16

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

Changxin Wan, Matthew P. Keany, Han Dong et al. · Cancer Research · 2020 · 215 citations · Full text

, , +17

In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target

Xiaoqing Wang, Collin Tokheim, Shengqing Gu et al. · Cell · 2021 · 198 citations · Full text

, , +12

1–5 of 39